Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.136321810.3389/fphar.2024.1363218PharmacologyCorrectionCorrigendum: Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/ FUT4 axis and P-Glycoprotein transporters in lung cancer cellsDing et al.10.3389/fphar.2024.1363218DingYaming1ZhenZhang2NisarMuhammad Azhar2AliFarman3DinRiaz Ud2KhanMuhammad4MughalTafail Akbar5AlamGulzar6LiuLinlin1*SaleemMuhammad Zubair27*1The Second Hospital of Jilin University, Changchun, China2College of Basic Medical Sciences, Dalian Medical University, Dalian, China3Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China4Institute of Zoology, University of the Punjab, Lahore, Pakistan5Medical Toxicology Laboratory, Department of Zoology, Women University of Azad Jammu and Kashmir, Muzaffarabad, Pakistan6Faculty of Rehabilitation and Allied Health Sciences, Riphah International University, Islamabad, Pakistan7Fujian Provincial Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou, China
Edited and reviewed by:Olivier Feron, Université catholique de Louvain, Belgium
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Sesquiterpene lactones attenuate paclitaxel resistance via inhibiting MALAT1/STAT3/ FUT4 axis and P-Glycoprotein Transporters in Lung Cancer Cells by Ding Y, Zhen Z, Nisar MA, Ali F, Din RU, Khan M, Mughal TA, Alam G, Liu L and Saleem MZ (2022). Front. Pharmacol. 13:795613. doi: 10.3389/fphar.2022.795613paclitaxel resistanceSTAT3FUT4P-gpMALAT1alantolactonebrevilin Asection-at-acceptancePharmacology of Anti-Cancer Drugs
In the published article, there was an error in Figures 5B,C as published. The striatum of Figures 5B,C in the article was not the final version. This may have been caused by an initial error in the image layout editing process. The molecular docking presentation in Figure 5B is duplicate of Figure 5A while Figure 5C is pasted incorrectly, however, the description of Figure 5 in the article is correct. The corrected Figure 5 and its caption appear below.
Molecular docking of ALT and Brv-A to determine their binding affinities with FUT4, and P-GP. (A, B) Molecular docking of ALT and Brv-A with FUT4. (C, D) Molecular docking of ALT and Brv-A with P-GP.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.